Adding radiation to chemotherapy for high-risk colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a short course of radiation to chemotherapy before surgery helps improve outcomes for people with high-risk colon cancer. Radiation is given along with chemotherapy, and the study compares this to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have colon cancer that has spread through the bowel wall or to nearby lymph nodes, but not to distant organs.
- Your tumor is more than 15 cm from the anal verge (confirmed by colonoscopy).
- Your cancer is pMMR or MSS (a specific genetic marker) confirmed by a test.
- You have not had any prior cancer treatment for this disease.
- Your overall health is good (able to care for yourself and up and about more than 50% of waking hours).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
This trial tests a shorter course of radiation given with chemotherapy and immunotherapy before surgery for rectal cancer that has high-risk features. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Hear when a new Locally Advanced Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.